Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.34 |
| ▸ | FGR | P09769 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423152 | 0.91 | CDK6 (0.41) | BTKCDK6CCND1YES1FGR | |
| SCHEMBL1422703 | 0.90 | CDK6 (0.40) | BTKCDK6CCND1YES1FGR | |
| SCHEMBL1422539 | 0.89 | BTK (0.39) | BTKCDK6CCND1YES1FGR | |
| SCHEMBL1422829 | 0.89 | CCND1 (0.40) | BTKCDK6CCND1YES1FGR | |
| SCHEMBL1423516 | 0.86 | BTK (0.52) | BTKYES1FGRTECBMX | |
| SCHEMBL1784125 | 0.86 | BTK (0.52) | BTKYES1FGRTECBMX | |
| SCHEMBL1423347 | 0.86 | BTK (0.52) | BTKYES1FGRTECBMX | |
| SCHEMBL1422358 | 0.85 | BTK (0.40) | BTKCDK6CCND1FGRTEC | |
| SCHEMBL1422769 | 0.83 | BTK (0.53) | BTKYES1FGRTECBMX | |
| SCHEMBL1422433 | 0.83 | BTK (0.39) | BTKCDK6CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | claimed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | BTK 1/4885CDK6 530/4885CCND1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.